Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer

The purpose of the study was to evaluate the efficacy and safety of docetaxel plus epirubicin (ET) and of 5-fluorouracil plus epirubicin and cyclophosphamide (FEC) as first-line chemotherapy for metastatic breast cancer. A total of 142 patients (intent-to-treat (ITT)) with at least one measurable le...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bonneterre, J, Dieras, V, Tubiana-Hulin, M, Bougnoux, P, Bonneterre, M-E, Delozier, T, Mayer, F, Culine, S, Dohoulou, N, Bendahmane, B
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2004
Témata:
Clinical
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409942/
https://ncbi.nlm.nih.gov/pubmed/15381937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602179
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky